A multi-database, self-controlled case series, postmarketing surveillance study of COVID-19 mRNA vaccines in subjects aged 12 to 39 years in Italy
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 22 Aug 2022 New trial record
- 01 Jul 2022 Results published in the PLOS Medicine